Levy Adam Scott 4

Accession 0001933414-25-000152

CIK 0001933414other

View on SEC.gov Company Profile

Filed

Nov 12, 7:00 PM ET

Accepted

Nov 13, 7:01 PM ET

Size

35.4 KB

Accession

0001933414-25-000152

Insider Transaction Report

Form 4

Period: 2025-11-11

Mineralys Therapeutics, Inc.MLYS

Levy Adam Scott

CFO and Secretary

Transactions

Sale
Common Stock
2025-11-11$45.18/sh−8,456$382,046→ 91,014 total
Exercise/Conversion
Common Stock
2025-11-11$10.20/sh+20,547$209,579→ 53,814 total
Exercise/Conversion
Common Stock
2025-11-11$14.25/sh+44,079$628,126→ 132,307 total
Sale
Common Stock
2025-11-11$42.00/sh−1,015$42,630→ 137,905 total
Sale
Common Stock
2025-11-11$42.68/sh−1,561$66,623→ 125,049 total
Sale
Common Stock
2025-11-11$42.34/sh−8,485$359,258→ 103,612 total
Exercise/Conversion
Common Stock
2025-11-11$16.00/sh+34,414$550,624→ 88,228 total
Sale
Common Stock
2025-11-11$41.87/sh−11,295$472,932→ 126,610 total
Exercise/Conversion
Stock Option
2025-11-11−44,079→ 91,592 total
Exercise: $14.25Exp: 2034-02-13→ Common Stock (44,079 underlying)
Exercise/Conversion
Common Stock
2025-11-11$15.44/sh+6,613$102,105→ 138,920 total
Sale
Common Stock
2025-11-11$45.93/sh−38,900$1,786,588→ 52,114 total
Exercise/Conversion
Stock Option
2025-11-11−34,414→ 20,662 total
Exercise: $16.00Exp: 2033-02-09→ Common Stock (34,414 underlying)
Sale
Common Stock
2025-11-11$46.88/sh−32,718$1,533,977→ 19,396 total
Exercise/Conversion
Stock Option
2025-11-11−6,613→ 4,888 total
Exercise: $15.44Exp: 2033-03-17→ Common Stock (6,613 underlying)
Sale
Common Stock
2025-11-11$41.65/sh−12,952$539,479→ 112,097 total
Sale
Common Stock
2025-11-11$43.50/sh−4,142$180,183→ 99,470 total
Exercise/Conversion
Stock Option
2025-11-11−20,547→ 135,674 total
Exercise: $10.20Exp: 2035-02-13→ Common Stock (20,547 underlying)

Footnotes (15)

[F1]Since the date of the Reporting Person's last ownership report, 83,598 shares of common stock were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
[F10]The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.
[F11]Since the date of the Reporting Person's last ownership report, 13,779 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
[F12]The stock option vests as to 25% of the total number of shares of common stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of common stock subject to the option on each monthly anniversary thereafter.
[F13]Since the date of the Reporting Person's last ownership report, 42,442 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
[F14]Since the date of the Reporting Person's last ownership report, 64,329 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
[F15]Since the date of the Reporting Person's last ownership report, 8,499 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.
[F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.4500 to $42.2800. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
[F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.5100 to $42.9150. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
[F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.0550 to $42.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
[F5]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.1000 to $43.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
[F6]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.1700 to $44.0500. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.
[F7]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.4700 to $45.4600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.
[F8]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.4800 to $46.4725. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.
[F9]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.4900 to $47.3600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9) to this Form 4.

Documents

1 file

4
wk-form4_1763078493.xmlPrimary
FORM 4

Issuer

Mineralys Therapeutics, Inc.

CIK 0001933414

→

Entity typeother

Related Parties

filerCIK 0001693134

Filing Metadata

Form type: 4
Filed: Nov 12, 7:00 PM ET
Accepted: Nov 13, 7:01 PM ET
Size: 35.4 KB

View on SEC.gov